Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14893201 | 0.91 | MAOB (0.50) | CYP4F2CYP4A11L3MBTL1MAOBALDH1A1 | |
| SCHEMBL10623418 | 0.89 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1MAOBGAA | |
| SCHEMBL19181 | 0.88 | CYP4F2 (0.54) | CYP4F2CYP4A11L3MBTL1MAOBALDH1A1 | |
| SCHEMBL25931692 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11L3MBTL1GAA | |
| SCHEMBL6665932 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11L3MBTL1GAA | |
| SCHEMBL10628068 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11L3MBTL1GAA | |
| SCHEMBL10627972 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11L3MBTL1GAA | |
| Ammonia Solution, Strong SCHEMBL10430550 | 0.86 | CYP4F2 (0.50) | CYP4F2CYP4A11L3MBTL1GAA | |
| SCHEMBL31558666 | 0.86 | CYP4F2 (0.47) | CYP4F2CYP4A11L3MBTL1ALDH1A1MAPT | |
| SCHEMBL3849886 | 0.86 | ALDH1A1 (0.54) | CYP4F2CYP4A11L3MBTL1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-01-22 | — | — | US | disclosed |
| US-12318413-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | disclosed |
| US-12310996-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4518647-A1 | WASP PEST MANAGEMENT SYSTEM | Toner, Daradh (IE) | 2025-03-12 | — | — | EP | disclosed |
| US-20240173361-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2023214095-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2023-11-09 | — | — | WO | disclosed |
| US-20230109343-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-06 | — | — | US | disclosed |
| US-11062794-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-07-13 | — | — | US | disclosed |
| US-20180253534-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-09-06 | — | — | US | disclosed |
| US-9959392-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| WO-2013035070-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-14 | — | — | WO | disclosed |
| US-20100047373-A9 | Method for Extracting Plants of the Genus Pelargonium, Extract Produced According to Said Method, and Use Thereof | EMSPHARM GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090035402-A1 | Method for Extracting Plants of the Genus Pelargonium, Extract Produced According to Said Method, and Use Thereof | EMSPHARM GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-1997026926-A1 | AIR FRESHENER COMPOSITION CONTAINING A FIBER PAD | EASTMAN CHEMICAL COMPANY (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | PDCD1, CD274, PDCD1LG2 | CYP4F2 2142/4885CYP4A11 1481/4885L3MBTL1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.